Risk factors
Spero Therapeutics (SPRO) risk factors
Item 1A of every Spero Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors75 risks11 new17 dropped20 reworded
Spero Therapeutics faces heightened operational risks regarding clinical trial uncertainties, debt financing needs, and external macroeconomic pressures like new tariffs and tax laws.
Filed Mar 26, 2026 - FY2024 10-K risk factors81 risks
Spero Therapeutics relies heavily on the success, regulatory approval, and commercialization of its lead product candidate tebipenem HBr under a partnership with GSK.
Filed Mar 27, 2025